Research Highlights for September 2023

Increasing access to Black people with prostate cancer may decrease mortality rate

In a study published in JAMA Network Open, researchers at Huntsman Cancer Institute found that making care more accessible to Black people with prostate cancer could decrease the mortality rate. Investigators had believed that since Black patients suffer from more aggressive forms of prostate cancer, their mortality rates were lower than White patients. Neeraj Agarwal, MD, FASCO, physician-scientist at Huntsman Cancer Institute, and his team showed that Black patients had similar survival outcomes to white patients when they had equal access to cancer care and treatment. 

First patient in a small cell lung cancer targeted therapy clinical trial treated

Huntsman Cancer Institute became the first U.S. facility to offer a phase 1 clinical trial for extensive stage small cell lung cancer with a targeted radiopharmaceutical therapy. Because small cell lung cancer is very aggressive, new targeted therapies are needed. When patients are considered for the clinical trial, they undergo a special scan. The scan helps assess whether they have the specific gene targeted by the drug. If the patient’s scan is positive, researchers can move forward with the targeted therapy. Sonam Puri, MD, physician-scientist at Huntsman Cancer Institute, leads the clinical trial.

Engaging adolescents and young adults with cancer through an app

The National Cancer Institute provided an R01 grant to Huntsman Cancer Institute investigators to conduct a multisite clinical trial to help adolescents and young adults (AYAs) manage their cancer symptoms. Lauri Linder, PhD, APRN, member of the Cancer Control and Population Sciences program at Huntsman Cancer Institute, created an app to engage AYAs to report their symptom experiences. AYAs use Dr. Linder’s app to create a diagram that shows the symptoms they are experiencing, how their symptoms are related, and which are most important to them. AYAs will use their symptom diagram during doctor visits to discuss and develop a plan to manage their symptoms. Dr. Linder’s team hopes to improve AYAs’ ability to manage their cancer-related symptoms. 

Reducing chemo side-effects after treatment

While receiving chemotherapy, it is common to experience cognitive issues, also known as chemo brain. These symptoms can occur during treatment, but often also persist for months or years post remission. In a study published in Digital Health, researchers found that cognitive games, developed at the University of Utah can improve memory, attention, and mood in women who experienced persistent chemo brain. Huntsman Cancer Institute researcher Sarah Shizuko Morimoto, PSYD, and her team, also noted that patients were able to accurately perceive their abilities and as their cognition improved, so did perception of their cognitive function.

About Huntsman Cancer Institute at the University of Utah

Huntsman Cancer Institute at the University of Utah (the U) is the official cancer center of Utah and the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West. The institute is leading the world in scientific discovery, and turning it into unsurpassed cancer care, transforming hope into a reality. Huntsman Cancer Institute focuses on delivering a cancer-free frontier to Utah, Idaho, Montana, Nevada, and Wyoming (The Area We Serve). Huntsman Cancer Institute is home to over 300 clinical trials, with over 237 research teams studying cancer at any given time and more genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Huntsman Cancer Institute’s scientists are world renown for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient’s unique tumor. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.